Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says

MT Newswires Live06-24

Verastem's (VSTM) update on its VS-7375 investigational KRAS G12D inhibitor reiterated its potential in US patients, setting the stage for further data validation in H2, RBC Capital Markets said in a note emailed Wednesday.

"Efficacy in ex-US patients should translate to US patients across major indications," the brokerage said, also noting VS-7375's clean safety profile. The company did not present formal tumor response data, but its efficacy data indicate VS-7375's potential to beat the overall response rate level of competing therapy zoldon, RBC said.

The company's upcoming development update in H2 could serve as a key catalyst, according to the investment firm. RBC estimates about a $1 billion opportunity for VS-7375 by 2035 across pancreatic, colorectal, and non-small cell lung cancers.

RBC maintained its outperform rating and $15 price target on Verastem.

Price: 4.39, Change: +0.18, Percent Change: +4.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645811763?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 23:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645811763","market":"nz","top_or_hot":-1,"title":"Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) update on its VS-7375 investigational KRAS G12D inhibitor reiterated its potential in US patients, setting the stage for further data validation in H2, RBC Capital Markets said in a note emailed Wednesday.</p><p>\"Efficacy in ex-US patients should translate to US patients across major indications,\" the brokerage said, also noting VS-7375's clean safety profile. The company did not present formal tumor response data, but its efficacy data indicate VS-7375's potential to beat the overall response rate level of competing therapy zoldon, RBC said.</p><p>The company's upcoming development update in H2 could serve as a key catalyst, according to the investment firm. RBC estimates about a $1 billion opportunity for VS-7375 by 2035 across pancreatic, colorectal, and non-small cell lung cancers.</p><p>RBC maintained its outperform rating and $15 price target on Verastem.</p><p>Price: 4.39, Change: +0.18, Percent Change: +4.16</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem's VS-7375 Update Reiterates Potential in US Patients, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-24 23:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/VSTM\">Verastem</a>'s (VSTM) update on its VS-7375 investigational KRAS G12D inhibitor reiterated its potential in US patients, setting the stage for further data validation in H2, RBC Capital Markets said in a note emailed Wednesday.</p><p>\"Efficacy in ex-US patients should translate to US patients across major indications,\" the brokerage said, also noting VS-7375's clean safety profile. The company did not present formal tumor response data, but its efficacy data indicate VS-7375's potential to beat the overall response rate level of competing therapy zoldon, RBC said.</p><p>The company's upcoming development update in H2 could serve as a key catalyst, according to the investment firm. RBC estimates about a $1 billion opportunity for VS-7375 by 2035 across pancreatic, colorectal, and non-small cell lung cancers.</p><p>RBC maintained its outperform rating and $15 price target on Verastem.</p><p>Price: 4.39, Change: +0.18, Percent Change: +4.16</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4085","symbol_name":"互动家庭娱乐","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2645811763","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645811763","pubTimestamp":1782313998,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Verastem's  update on its VS-7375 investigational KRAS G12D inhibitor reiterated its potential in US patients, setting the stage for further data validation in H2, RBC Capital Markets said in a note emailed Wednesday.\"Efficacy in ex-US patients should translate to US patients across major indications,\" the brokerage said, also noting VS-7375's clean safety profile. The company did not present formal tumor response data, but its efficacy data indicate VS-7375's potential to beat the overall response rate level of competing therapy zoldon, RBC said.The company's upcoming development update in H2 could serve as a key catalyst, according to the investment firm. RBC estimates about a $1 billion opportunity for VS-7375 by 2035 across pancreatic, colorectal, and non-small cell lung cancers.RBC maintained its outperform rating and $15 price target on Verastem.Price: 4.39, Change: +0.18, Percent Change: +4.16","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4085":"互动家庭娱乐","VS":"Versus Systems Inc.","VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"RBC表示，Verastem的VS-7375更新重申了在美国患者中的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VS":1.5,"VSTM":1.5},"content_text":"Verastem's (VSTM) update on its VS-7375 investigational KRAS G12D inhibitor reiterated its potential in US patients, setting the stage for further data validation in H2, RBC Capital Markets said in a note emailed Wednesday.\"Efficacy in ex-US patients should translate to US patients across major indications,\" the brokerage said, also noting VS-7375's clean safety profile. The company did not present formal tumor response data, but its efficacy data indicate VS-7375's potential to beat the overall response rate level of competing therapy zoldon, RBC said.The company's upcoming development update in H2 could serve as a key catalyst, according to the investment firm. RBC estimates about a $1 billion opportunity for VS-7375 by 2035 across pancreatic, colorectal, and non-small cell lung cancers.RBC maintained its outperform rating and $15 price target on Verastem.Price: 4.39, Change: +0.18, Percent Change: +4.16","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645811763","isCrawlerRequest":true}